Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.

Shearer JD, Saylor ML, Butler CM, Treston AM, Heine HS, Chirakul S, Schweizer HP, Louie A, Drusano GL, Zumbrun SD, Warfield KL.

Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.00834-19. doi: 10.1128/AAC.00834-19. [Epub ahead of print]

2.

Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B.

Warfield KL, Schaaf KR, DeWald LE, Spurgers KB, Wang W, Stavale E, Mendenhall M, Shilts MH, Stockwell TB, Barnard DL, Ramstedt U, Das SR.

Sci Rep. 2019 May 16;9(1):7484. doi: 10.1038/s41598-019-43030-y.

3.

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.

Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ.

J Infect Dis. 2018 Nov 22;218(suppl_5):S553-S564. doi: 10.1093/infdis/jiy316.

PMID:
29939318
4.

Iminosugars: Promising therapeutics for influenza infection.

Tyrrell BE, Sayce AC, Warfield KL, Miller JL, Zitzmann N.

Crit Rev Microbiol. 2017 Sep;43(5):521-545. doi: 10.1080/1040841X.2016.1242868. Epub 2016 Dec 8. Review.

5.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
6.

Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.

Chen WH, Pasetti MF, Adhikari RP, Baughman H, Douglas R, El-Khorazaty J, Greenberg N, Holtsberg FW, Liao GC, Reymann MK, Wang X, Warfield KL, Aman MJ.

Clin Vaccine Immunol. 2016 Dec 5;23(12):918-925. Print 2016 Dec.

7.

Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.

Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK.

Hepatology. 2016 Dec;64(6):1922-1933. doi: 10.1002/hep.28850. Epub 2016 Oct 28.

8.

The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice.

Warfield KL, Barnard DL, Enterlein SG, Smee DF, Khaliq M, Sampath A, Callahan MV, Ramstedt U, Day CW.

Viruses. 2016 Mar 7;8(3):71. doi: 10.3390/v8030071.

9.

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).

Dye JM, Warfield KL, Wells JB, Unfer RC, Shulenin S, Vu H, Nichols DK, Aman MJ, Bavari S.

Viruses. 2016 Apr 8;8(4):94. doi: 10.3390/v8040094.

10.

Role of small biotechnology companies in the fledgling biodefense vaccine industry.

Warfield KL, Aman MJ.

Expert Rev Vaccines. 2016 Sep;15(9):1079-1082. Epub 2016 Apr 11. No abstract available.

PMID:
26998722
11.

Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.

Warfield KL, Plummer EM, Sayce AC, Alonzi DS, Tang W, Tyrrell BE, Hill ML, Caputo AT, Killingbeck SS, Beatty PR, Harris E, Iwaki R, Kinami K, Ide D, Kiappes JL, Kato A, Buck MD, King K, Eddy W, Khaliq M, Sampath A, Treston AM, Dwek RA, Enterlein SG, Miller JL, Zitzmann N, Ramstedt U, Shresta S.

Antiviral Res. 2016 May;129:93-98. doi: 10.1016/j.antiviral.2016.03.001. Epub 2016 Mar 3.

12.

Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.

Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW.

Antiviral Res. 2016 Feb;126:55-61. doi: 10.1016/j.antiviral.2015.11.012. Epub 2015 Dec 8.

13.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ.

J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.

14.

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.

Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ.

J Virol. 2015 Oct 14;90(1):279-91. doi: 10.1128/JVI.02172-15. Print 2016 Jan 1.

15.

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Oct 9;11(10):e1005212. doi: 10.1371/journal.ppat.1005212. eCollection 2015 Oct. No abstract available.

16.

AVI-7288 for Marburg Virus in Nonhuman Primates and Humans.

Heald AE, Charleston JS, Iversen PL, Warren TK, Saoud JB, Al-Ibrahim M, Wells J, Warfield KL, Swenson DL, Welch LS, Sazani P, Wong M, Berry D, Kaye EM, Bavari S.

N Engl J Med. 2015 Jul 23;373(4):339-48. doi: 10.1056/NEJMoa1410345.

17.

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Jun 26;11(6):e1005016. doi: 10.1371/journal.ppat.1005016. eCollection 2015 Jun. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005212. Berry, Jody [corrected to Berry, Jody D].

18.

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2015;11(8):1991-2004. doi: 10.1080/21645515.2015.1039757.

19.

A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue).

Warfield KL, Plummer E, Alonzi DS, Wolfe GW, Sampath A, Nguyen T, Butters TD, Enterlein SG, Stavale EJ, Shresta S, Ramstedt U.

Viruses. 2015 May 13;7(5):2404-27. doi: 10.3390/v7052404.

20.

Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ.

PLoS One. 2015 Mar 20;10(3):e0118881. doi: 10.1371/journal.pone.0118881. eCollection 2015.

21.

In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4.

Stavale EJ, Vu H, Sampath A, Ramstedt U, Warfield KL.

PLoS One. 2015 Mar 18;10(3):e0121662. doi: 10.1371/journal.pone.0121662. eCollection 2015.

22.

Dengue Virus Evolution under a Host-Targeted Antiviral.

Plummer E, Buck MD, Sanchez M, Greenbaum JA, Turner J, Grewal R, Klose B, Sampath A, Warfield KL, Peters B, Ramstedt U, Shresta S.

J Virol. 2015 May;89(10):5592-601. doi: 10.1128/JVI.00028-15. Epub 2015 Mar 11.

23.

The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication.

Carocci M, Hinshaw SM, Rodgers MA, Villareal VA, Burri DJ, Pilankatta R, Maharaj NP, Gack MU, Stavale EJ, Warfield KL, Yang PL.

Antimicrob Agents Chemother. 2015 Jan;59(1):85-95. doi: 10.1128/AAC.04177-14. Epub 2014 Oct 13.

24.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

25.

Vaccinating captive chimpanzees to save wild chimpanzees.

Warfield KL, Goetzmann JE, Biggins JE, Kasda MB, Unfer RC, Vu H, Aman MJ, Olinger GG Jr, Walsh PD.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8873-6. doi: 10.1073/pnas.1316902111. Epub 2014 May 27.

26.

Induced IL-10 splice altering approach to antiviral drug discovery.

Panchal RG, Mourich DV, Bradfute S, Hauck LL, Warfield KL, Iversen PL, Bavari S.

Nucleic Acid Ther. 2014 Jun;24(3):179-85. doi: 10.1089/nat.2013.0457. Epub 2014 Mar 21.

PMID:
24655055
27.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2. Epub 2013 Nov 5.

28.

Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model.

Karauzum H, Adhikari RP, Sarwar J, Devi VS, Abaandou L, Haudenschild C, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Warfield KL, Shulenin S, Aman MJ.

PLoS One. 2013 Jun 7;8(6):e65384. doi: 10.1371/journal.pone.0065384. Print 2013.

29.

An iminosugar with potent inhibition of dengue virus infection in vivo.

Perry ST, Buck MD, Plummer EM, Penmasta RA, Batra H, Stavale EJ, Warfield KL, Dwek RA, Butters TD, Alonzi DS, Lada SM, King K, Klose B, Ramstedt U, Shresta S.

Antiviral Res. 2013 Apr;98(1):35-43. doi: 10.1016/j.antiviral.2013.01.004. Epub 2013 Jan 31.

PMID:
23376501
30.

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2013 Jun;158(6):1425-32. doi: 10.1007/s00705-012-1594-2. Epub 2013 Jan 29. No abstract available.

31.

Mouse models for filovirus infections.

Bradfute SB, Warfield KL, Bray M.

Viruses. 2012 Sep;4(9):1477-508. doi: 10.3390/v4091477. Epub 2012 Sep 7. Review.

32.

Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection.

Amman BR, Carroll SA, Reed ZD, Sealy TK, Balinandi S, Swanepoel R, Kemp A, Erickson BR, Comer JA, Campbell S, Cannon DL, Khristova ML, Atimnedi P, Paddock CD, Crockett RJ, Flietstra TD, Warfield KL, Unfer R, Katongole-Mbidde E, Downing R, Tappero JW, Zaki SR, Rollin PE, Ksiazek TG, Nichol ST, Towner JS.

PLoS Pathog. 2012;8(10):e1002877. doi: 10.1371/journal.ppat.1002877. Epub 2012 Oct 4.

33.

Research and analytics in combat trauma care: converting data and experience to practical guidelines.

Perkins JG, Brosch LR, Beekley AC, Warfield KL, Wade CE, Holcomb JB.

Surg Clin North Am. 2012 Aug;92(4):1041-54, x. doi: 10.1016/j.suc.2012.04.004. Epub 2012 May 31. Review.

PMID:
22850161
34.

Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia.

Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Devi VS, Shulenin S, Warfield KL, Aman MJ.

PLoS One. 2012;7(6):e38567. doi: 10.1371/journal.pone.0038567. Epub 2012 Jun 6.

35.

Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome.

Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, Roy CJ, Sidhu SS, Aman MJ.

J Biol Chem. 2012 Jul 20;287(30):25203-15. doi: 10.1074/jbc.M112.364075. Epub 2012 May 29.

36.

Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.

Warfield KL, Olinger GG.

J Biomed Biotechnol. 2011;2011:984241. doi: 10.1155/2011/984241. Epub 2011 Dec 28. Review.

37.

Advances in virus-like particle vaccines for filoviruses.

Warfield KL, Aman MJ.

J Infect Dis. 2011 Nov;204 Suppl 3:S1053-9. doi: 10.1093/infdis/jir346. Review.

38.

Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles.

Hu L, Trefethen JM, Zeng Y, Yee L, Ohtake S, Lechuga-Ballesteros D, Warfield KL, Aman MJ, Shulenin S, Unfer R, Enterlein SG, Truong-Le V, Volkin DB, Joshi SB, Middaugh CR.

J Pharm Sci. 2011 Dec;100(12):5156-73. doi: 10.1002/jps.22724. Epub 2011 Aug 19.

PMID:
21858822
39.

Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.

Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, Bradfute SB, Gearhart JD, Retterer C, Kranzusch PJ, Misasi JN, Hogenbirk MA, Wahl-Jensen V, Volchkov VE, Cunningham JM, Jahrling PB, Aman MJ, Bavari S, Farzan M, Kuhn JH.

J Virol. 2011 Sep;85(17):8502-13. doi: 10.1128/JVI.02600-10. Epub 2011 Jun 22.

40.

Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.

Lofts LL, Wells JB, Bavari S, Warfield KL.

J Virol. 2011 Apr;85(8):3905-17. doi: 10.1128/JVI.02372-10. Epub 2011 Feb 2.

41.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich DV, Crumley S, Nichols DK, Iversen PL, Bavari S.

Nat Med. 2010 Sep;16(9):991-4. doi: 10.1038/nm.2202. Epub 2010 Aug 22.

PMID:
20729866
42.

Antiviral activity of a small-molecule inhibitor of filovirus infection.

Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S.

Antimicrob Agents Chemother. 2010 May;54(5):2152-9. doi: 10.1128/AAC.01315-09. Epub 2010 Mar 8.

43.

Ebola virus uses clathrin-mediated endocytosis as an entry pathway.

Bhattacharyya S, Warfield KL, Ruthel G, Bavari S, Aman MJ, Hope TJ.

Virology. 2010 May 25;401(1):18-28. doi: 10.1016/j.virol.2010.02.015. Epub 2010 Mar 3.

44.

Discovery of common marburgvirus protective epitopes in a BALB/c mouse model.

Kalina WV, Warfield KL, Olinger GG, Bavari S.

Virol J. 2009 Aug 27;6:132. doi: 10.1186/1743-422X-6-132.

45.

Reduced levels of protein tyrosine phosphatase CD45 protect mice from the lethal effects of Ebola virus infection.

Panchal RG, Bradfute SB, Peyser BD, Warfield KL, Ruthel G, Lane D, Kenny TA, Anderson AO, Raschke WC, Bavari S.

Cell Host Microbe. 2009 Aug 20;6(2):162-73. doi: 10.1016/j.chom.2009.07.003.

46.

Filovirus infections.

Warfield KL, Deal EM, Bavari S.

J Am Vet Med Assoc. 2009 May 1;234(9):1130-9. doi: 10.2460/javma.234.9.1130. Review. No abstract available.

PMID:
19405883
47.

Development and characterization of a mouse model for Marburg hemorrhagic fever.

Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S.

J Virol. 2009 Jul;83(13):6404-15. doi: 10.1128/JVI.00126-09. Epub 2009 Apr 15.

48.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

49.

Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.

Kortepeter MG, Martin JW, Rusnak JM, Cieslak TJ, Warfield KL, Anderson EL, Ranadive MV.

Emerg Infect Dis. 2008 Jun;14(6):881-7. doi: 10.3201/eid1406.071489.

50.

Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.

Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S.

Expert Rev Vaccines. 2008 May;7(4):417-29. doi: 10.1586/14760584.7.4.417.

PMID:
18444889

Supplemental Content

Loading ...
Support Center